Preoperative Biomarker Panel, Including Fibrinogen and FVIII, Improves Diagnostic Accuracy for Pancreatic Ductal Adenocarcinoma

Show full item record



Permalink

http://hdl.handle.net/10138/251195

Citation

Mattila , N , Seppänen , H , Mustonen , H , Przybyla , B , Haglund , C & Lassila , R 2018 , ' Preoperative Biomarker Panel, Including Fibrinogen and FVIII, Improves Diagnostic Accuracy for Pancreatic Ductal Adenocarcinoma ' , Clinical and Applied Thrombosis / Hemostasis , vol. 24 , no. 8 , pp. 1267-1275 . https://doi.org/10.1177/1076029618779133

Title: Preoperative Biomarker Panel, Including Fibrinogen and FVIII, Improves Diagnostic Accuracy for Pancreatic Ductal Adenocarcinoma
Author: Mattila, Nora; Seppänen, Hanna; Mustonen, Harri; Przybyla, Beata; Haglund, Caj; Lassila, Riitta
Contributor: University of Helsinki, II kirurgian klinikka
University of Helsinki, Clinicum
University of Helsinki, HUS Comprehensive Cancer Center
University of Helsinki, Translational Cancer Biology (TCB) Research Programme
University of Helsinki, Clinicum
Date: 2018-11
Language: eng
Number of pages: 9
Belongs to series: Clinical and Applied Thrombosis / Hemostasis
ISSN: 1076-0296
URI: http://hdl.handle.net/10138/251195
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer often diagnosed late. Earlier detection is urgently needed. Pancreatic ductal adenocarcinoma is known to associate with increased coagulation activity. We studied whether preoperative coagulation biomarkers are useful in distinguishing PDAC from a benign tumor, intraductal papillary mucinous neoplasm (IPMN) in this observational study. We analyzed standard clinical and coagulation variables in patients operated during 2010 and 2015 at Helsinki University Hospital. Pancreatic ductal adenocarcinoma with preoperative coagulation variables available and no neoadjuvant treatment or other active cancer was observed in 80 patients (stage I-III in 67 and IV in 13) and IPMN in 18 patients. Fibrinogen, factor VIII (FVIII), carbohydrate antigen (CA) 19-9, albumin, alkaline phosphatase, and conjugated bilirubin were higher in both stages I to III and IV PDAC compared to IPMN (P <.05). Factor VIII was highest in stage IV (P <.05). Combining these variables in a panel increased sensitivity and specificity for PDAC. In receiver operating characteristic analysis, the area under the curve (95% confidence interval) was 0.95 (0.90-1.00) for the panel, compared to 0.80 (0.71-0.88) for CA 19-9 alone (P <.01). In conclusion, PDAC was associated with increased fibrinogen and FVIII. Combining these coagulation biomarkers with CA 19-9, albumin, and alkaline phosphatase improves diagnostic accuracy.
Subject: pancreatic cancer
coagulation
CA 19-9
fibrinogen
FVIII
biomarker
D-DIMER LEVELS
VENOUS THROMBOEMBOLISM
CANCER-PATIENTS
CLINICAL-ASPECTS
TUMOR-CELLS
RISK
SURVIVAL
COAGULATION
THROMBOSIS
CA-19-9
3122 Cancers
3111 Biomedicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1076029618779133.pdf 336.7Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record